BioSpace News Archive

The NASH market is expected to evolve because of emerging therapies like MGL-3196, Semaglutide, Vonafexor, HPG1860, VK2809, BIO89-100, LPCN 1144, and others.

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a medical device company commercializing IzoView, a CT (computed tomography) imaging system, that produces images of anatomy

ASH is the world leader in supporting clinical and scientific hematology research

Uvax Bio, LLC, a privately held, preclinical-stage vaccine company, announced that the International Union of Pure and Applied Chemistry has selected the glycan trimming technology used by Prof. Jiang Zhu of Scripps Research, Co-founder and Chief Scientific Officer of Uvax Bio in his innovative design of HIV-1 vaccines to improve immune recognition as one of the Top Ten Emerging Technologies in Chemistry for 2023.

HuidaGene Therapeutics today announced the first patient has been dosed in the multinational, master-protocol Phase 1/2a clinical trial (NCT05906953; CTR20232920) of HG004 gene therapy drug, or the STAR (Safety and efficacy Trial of HG004 for leber congenital Amaurosis related to Rpe65 gene mutations) study, an adeno-associated virus 9 (AAV9) gene replacement therapy candidate for the treatment of inherited retinal dystrophies caused by RPE65 mutations (RPE65-IRD).

BioAro Inc., an innovative biotechnology company headquartered in downtown Calgary, Canada, is on a mission to revolutionize the approach to Irritable Bowel Syndrome (IBS) treatment by facilitating worldwide access to microbiome testing and telemedicine.

Nicklaus Children’s Hospital announced it has treated its first patient with ELEVIDYS (delandistrogene moxeparvovec-rokl), the first gene therapy for Duchenne muscular dystrophy.

Nortech Systems Incorporated, a leading provider of engineering and manufacturing solutions for complex electromedical and electromechanical products announced two new members were elected to Nortech’s board of directors.

Peel Therapeutics, a clinical stage biotech company developing evolutionary based medicines, will present data on its lead clinical asset, PEEL-224, at two conferences this week.

Siren Biotechnology announced that the California Institute for Regenerative Medicine has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene therapies for cancer.